Use of soluble costimulatory factor for tumor immuno-gene therapy
US7064111B1 · kind B1 · utility
5Cited by
3References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 5, 2000 |
| Grant date | Jun 20, 2006 |
| Priority date | — |
| Expiry date | Oct 22, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16643
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A new gene therapy entails tumor treatment by introducing an expressible nucleotide sequence for a soluble costimulatory factor, thereby enhancing the response of T-cells to a tumor. In vivo expression of the soluble factor overcomes anergy or tolerance to tumor cells and activates T-cells that are infiltrating or surrounding the tumor. A pharmaceutical composition containing such a gene is effective in tumor suppression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.